In 2017, the FDA approved semaglutide, an injectable GLP-1 agonist medication sold under the name Ozempic, for the management of type 2 diabetes. Later, the pharmaceutical company that makes Ozempic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results